BioSpace News Archive

Drug Development

Identifying Missing Links - and Why Certain Drugs Don’t Work - in Alzhiemer’s

A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons.

March 30, 2022
·
5 min read
·
Mark Terry
Drug Development

Biogen Submits Final Plan for Confirmatory Aduhelm Trial

Biogen will await word after submitting the final study protocol for its confirmatory Phase IV ENVISION trial of Aduhelm to the U.S. Food and Drug Administration (FDA).

March 30, 2022
·
2 min read
·
Vanessa Doctor, MS
FDA

Honing in On Neurometabolic Diseases, Orchard Slashes 30% of Workforce

Orchard Therapeutics announced today that it intends to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs.

March 30, 2022
·
2 min read
·
Hayley Shasteen
Business

Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA

Merck announced that it will be laying off 143 people from the Cambridge, Massachusetts-based Acceleron.

March 30, 2022
·
3 min read
·
Mark Terry
Money on the Move: March 23-29

This week, money moved in the form of equity financing, upfront partnership payments, nonprofit donations and federal funding.

March 30, 2022
·
4 min read
·
Hannah Chudleigh
Drug Development

Spirit of ALS Patient Drives NeuroSense Mission to Bring PrimeC to Market

A meeting with an amyotrophic lateral sclerosis (ALS) patient in Israel who could only speak with the assistance of a computer changed the life and direction of NeuroSense CEO Alon Ben-Noon.

March 30, 2022
·
4 min read
·
Alex Keown
Drug Development

Safety Concerns Doom Akebia’s Chronic Kidney Disease Drug

The FDA has rejected Cambridge, Mass.-based Akebia Therapeutics’ New D2rug Application (NDA) for vadadustat, a therapeutic for anemia due to chronic kidney disease (CKD).

March 30, 2022
·
2 min read
·
Rosemary Scott
Drug Development

Amylyx ALS Candidate Denied in Painfully Close AdCom Vote (Updated)

In a meeting of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee, six members voted not to approve the NDA for Amylyx’s ALS candidate, AMX0035, while four voted in favor.

March 30, 2022
·
4 min read
·
Heather McKenzie
Eye Allergy Therapeutics Market Projection and Upcoming Trends 2022 | Global Industry Survey

By acting on the H1 receptors, which produce antibodies from the mast cell, traditional eye allergy therapies assist to reduce the symptoms and signs of ocular allergies.

March 30, 2022
·
7 min read
Electrophoresis Market: Surge in awareness about personalized therapeutics to drive the market

Albany NY, United States: Electrophoresis technique is used to physically separate macromolecules such as RNA, nucleic acid fragments, and proteins according to their molecular size and electric charge.

March 30, 2022
·
5 min read